GGrantIndex
← Leaderboards

Katherine Elena Varley

University Of Utah

$4,277,906
Attributed
$7,610,102
Total exposure
3
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201624
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$7,610,102 · 3

By mechanism

U01$4,226,076 · 1
R01$2,354,401 · 1
UH3$1,029,625 · 1

Top collaborators

Most similar at University Of Utah

Same institution · by research overlap

Others in their field

Top investigators on “Specimen

Research focus

SpecimenMalignant Breast NeoplasmTumorSamplingBreast Cancer PatientDna MethylationIndividual PatientGenomicsFrequenciesMolecularMutationNeoadjuvant TherapyMammary NeoplasmsPatient CareGene ExpressionSpecificityReportingClia CertifiedResearch Clinical TestingBiological MarkersOncologistLaboratoriesRecurrenceDiagnosis

Grant awards (13)

Validation of the MHC II Immune Activation Assay in Breast Cancer$333,931
UH3 · FY2024 · CA · contact PI
Validation of the MHC II Immune Activation Assay in Breast Cancer$344,474
UH3 · FY2023 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$806,283
U01 · FY2022 · CA
Validation of the MHC II Immune Activation Assay in Breast Cancer$351,220
UH3 · FY2022 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$812,870
U01 · FY2021 · CA
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$986,128
U01 · FY2020 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$472,123
R01 · FY2020 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$798,057
U01 · FY2019 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$457,959
R01 · FY2019 · CA · contact PI
Longitudinal models of breast cancer for studying mechanisms of therapy response and resistance$822,738
U01 · FY2018 · CA
A partnership to enable clinical ctDNA testing for breast cancer recurrence$472,123
R01 · FY2018 · CA · contact PI
A partnership to enable clinical ctDNA testing for breast cancer recurrence$470,203
R01 · FY2017 · CA · contact PI
A partnership to enable clinical ctDNA testing for breast cancer recurrence$481,993
R01 · FY2016 · CA · contact PI